title: [Pyoderma gangrenosum aggravated by GM-CSF administration].
authors.affiliation: Service de Dermatologie, CHU, Saint-Etienne, Hôpital Nord, Saint-Priest-en-Jarez.
authors.forename: J L
authors.initials: JL
authors.lastname: Perrot
authors.forename: F
authors.initials: F
authors.lastname: Benoit
authors.forename: D
authors.initials: D
authors.lastname: Segault
authors.forename: J
authors.initials: J
authors.lastname: Jaubert
authors.forename: D
authors.initials: D
authors.lastname: Guyotat
authors.forename: A
authors.initials: A
authors.lastname: Claudy
mesh_terms: D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D009503:Neutropenia / Q000188:drug therapy / Q000503:physiopathology; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D016178:Granulocyte-Macrophage Colony-Stimulating Factor
vernacular_title: Pyoderma gangrenosum aggravé par administration de GM-CSF.